AI Is Eating Regulated Industries — And That's a Signal for Where to Build Next

Three of the most valuable AI researchers in the world just left their $500K-plus jobs to build in an industry where you can’t ship a product without a decade of regulatory approval. That’s not a career mistake — it’s a signal.

Miles Wang left OpenAI to launch a drug discovery startup at a $2 billion valuation. Anthropic is developing drugs directly with Claude Science. Google DeepMind spinout Isomorphic Labs raised $2.1 billion. Chai Discovery hit a $3.8 billion valuation. This isn’t a trend — it’s a coordinated migration of AI talent into the most locked-down industries on the planet. And if you’re a solo builder, the implications go way beyond biotech. I covered Wang’s original move when the news broke, but the bigger picture is what matters here.

The pattern nobody’s connecting

Look at where AI researchers are going — not just in pharma. Finance teams are hiring ML engineers at record rates. Energy companies are building internal AI divisions. Insurance, logistics, agriculture, legal — every industry that used to be “too regulated for tech” is now a target.

The reason is simple: these industries have massive, untapped datasets that have never been properly modeled. Drug trial data. Financial transaction histories. Crop yield records spanning decades. Insurance claims databases. The data has been sitting there, locked behind compliance requirements and legacy systems, waiting for someone to build the right model on top of it.

Foundation model labs figured this out first. They realized that the next wave of AI revenue won’t come from better chatbots — it’ll come from applying transformer architectures to industries where a 1% improvement translates to billions in value. A model that’s 1% better at predicting which existing drugs could treat new diseases? That’s worth more than every AI writing tool combined.

Why this matters if you’re building solo

You’re probably not going to launch a drug discovery startup. But the talent migration tells you something important about where AI tools are heading — and where the opportunities are for builders who don’t have a billion-dollar budget.

The tools follow the talent. When OpenAI researchers move into pharma, they don’t stop using AI tools — they bring them along. The infrastructure they build for drug discovery creates APIs, workflows, and platforms that eventually get abstracted into tools anyone can use. Claude Science is already a workbench that pulls research tools into one environment. How long before something similar exists for legal research, financial analysis, or supply chain optimization?

Regulated industries need automation the most. A solo consultant who figures out how to automate compliance workflows, regulatory filings, or data analysis for a specific vertical is sitting on a goldmine. These industries are drowning in manual processes, and the people working in them have budget but no technical skills. That’s exactly the gap solo builders can fill.

The “no-code” barrier is dropping fast. AI model regulation is slowing down foundation model releases, but it’s not slowing down tool development. The no-code layer between raw AI capability and end-user application is getting thicker every month. You don’t need to understand transformer architectures to build a workflow that automates a pharmaceutical company’s literature review process — you just need to know the tools.

Where the opportunities actually are

Here’s what I’d be looking at if I were starting fresh today:

Compliance automation. Every regulated industry has a documentation problem. FDA submissions. SEC filings. GDPR audits. These are repetitive, rules-based processes that AI handles well. A solo builder who creates a Make.com workflow that automates 80% of a compliance officer’s paperwork is building a real business.

Vertical-specific data tools. General-purpose AI tools are great, but specialists pay more. A tool that uses AI to analyze clinical trial data, parse legal contracts, or optimize supply chain routes commands higher prices than another generic chatbot wrapper. The knowledge of which data matters in a specific industry is the moat.

Bridge tools between AI labs and practitioners. The biggest gap in regulated industries isn’t AI capability — it’s accessibility. Researchers at pharmaceutical companies don’t know how to use Claude effectively. Lawyers don’t know what GPT can actually do for them. Building tools that translate AI capability into industry-specific workflows is a massive opportunity.

AI agent workflows for professionals. Imagine an AI agent that monitors new drug trial results, flags relevant findings for a specific therapeutic area, and drafts a summary for a pharmaceutical executive. Or one that tracks regulatory changes across multiple jurisdictions and updates a compliance checklist automatically. These are solo-builder-scale projects that serve high-value customers.

What not to do

Don’t try to build the AI model. You’re not competing with Isomorphic Labs’ $2.1 billion budget. The smart play Wang made — repurposing existing compounds instead of inventing new ones — applies to tool building too. Repurpose existing AI capabilities for new contexts.

Don’t chase the hype without a vertical. “AI for healthcare” is too broad. “AI-powered literature review automation for clinical researchers studying oncology” is a business. Specificity is how solo builders compete with well-funded startups — you go narrow where they can’t afford to.

Don’t ignore the privacy implications. Regulated industries have strict data handling requirements. If you’re building tools that touch patient data, financial records, or legal documents, you need to understand HIPAA, SOX, and GDPR from day one. This is actually a competitive advantage — most AI tool builders skip this, which means the ones who don’t immediately stand out.

The bottom line

The AI talent migration into regulated industries isn’t just biotech news. It’s a signal that AI’s next growth wave will happen in the most boring, most locked-down, most manual-process-heavy industries on the planet. And those industries need tools built by people who understand their specific problems — not by foundation model labs building general-purpose platforms.

If you’re a solo builder looking for your next project, stop building another AI writing assistant. Start looking at the industries where a 10% efficiency improvement is worth six figures to the person paying for it. The researchers who left OpenAI figured out where the value is. You can follow the same signal.

Ready to start building? Check out our beginner’s guide to AI workflows — no technical background required.